-
-
-
-
-
-
-
BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates
-
-
-
-
-
-
-
BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business Update
-
-
-
-
-
-
-
BridgeBio Pharma Reports Second Quarter 2024 Financial Results and Business Update
-
-
-
-
-
-
-
BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardi
-
-
-
-
-
-
-
BridgeBio Pharma's (BBIO) QED Therapeutics Receives Fast Track Designation for Infigratinib in Adults with First-Line Advanced or Metastatic Cholangiocarcinoma and Orphan Drug Designation for Infigrat
-
-
15,578 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

